Advertisement
Advertisement


News

The Search for a Cure

February 2017

 < Prev  |  1  |  2 

References

  1. Rocky S. What are the chances of getting funded? National Institutes of Health -- Office of Extramural Research. Extramural Nexus. 29 June 2015. Available at: https://nexus.od.nih.gov/all/2015/06/29/what-are-the-chances-of-getting-funded/
  2. Paules CI, Fauci AS. Emerging and re-emerging infectious diseases: The dichotomy between acute outbreaks and chronic endemicity. JAMA. 2017; in press.
  3. Rosen J. How $1.1 billion will be spent on Zika. Miami Herald. 29 September 2017. Available at: www.miamiherald.com/news/health-care/article104871266.html
  4. Tooze A. A general logic of crisis. London Review of Books. 2017 Jan 05;39(1):3-8. Available at: www.lrb.co.uk/v39/n01/adam-tooze/a-general-logic-of-crisis
  5. Branswell H. A superbug resistant to every available antibiotic in the U.S. kills Nevada woman. PBS News hour. 13 January, 2017. Available at: www.pbs.org/newshour/rundown/superbug-resistant-every-available-antibiotic-u-s-kills-nevada-woman/
  6. Evans D. An activist's argument that participant values should guide risk-benefit ratio calculations in HIV cure research. Journal of Medical Ethics. 2017; in press.
  7. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5 delta32/delta32 stem cell transplantation. Blood. 2011 Mar 10;117(10):2791-9.
  8. Hütter G, Bodor J, Ledger S, et al. CCR5 Targeted cell therapy for HIV and prevention of viral escape. Viruses. 2015 Jul 27;7(8):4186-203.
  9. Hütter G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. New England Journal of Medicine.  2014 Dec 18;371(25):2437-8.
  10. Caskey M, Schoofs T, Gruell H, et al.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine. 2017; in press.
  11. Martin GE, Gossez M, Williams JP, et al. Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. AIDS. 2017; in press.
  12. Klemm V, Mitchell J, Cortez-Jugo C, et al. Achieving HIV-1 control through RNA-directed gene regulation. Genes. 2016 Dec 7;7(12). pii: E119.
  13. Dental C, Proust A, Ouellet M, et al. HIV-1 Latency-reversing agents prostratin and bryostatin-1 induce blood-brain barrier disruption/inflammation and modulate leukocyte adhesion/transmigration. Journal of Immunology. 2016; in press.
  14. Gama L, Abreu CM, Shirk EN, et al. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS. 2017 Jan 2;31(1):5-14.
  15. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. New England Journal of Medicine. 2016 Nov 3;375(18):1767-1778.
  16. Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection.  PLoS Pathogens. 2016 Jan 7;12(1):e1005349.
  17. Fromentin R, Bakeman W, Lawani MB, et al. CD4+ T Cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathogens. 2016 Jul 14;12(7):e1005761.
  18. Tauriainen J, Scharf L, Frederiksen J, et al. Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Scientific Reports. 2017 Jan 13;7:40354.
  19. Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR) Modified T cells and induces tumor regression: Refueling the CAR. Blood. 2017; in press.
  20. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunology Today. 1990 Nov;11(11):406-10.
  21. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunology Letters. 2007 Jan 15;108(1):45-51.
  22. Rosenberg YJ, Zack PM, White BD, et al. Decline in the CD4+ lymphocyte population in the blood of SIV-infected macaques is not reflected in lymph nodes. AIDS Research and Human Retroviruses. 1993 Jul;9(7):639-46.
  23. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proceedings of the National Academy of Sciences USA. 1991 Nov 1;88(21):9838-42.
  24. Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation: The impact of highly active antiretroviral therapy. Journal of Experimental Medicine. 1998 Mar 16;187(6):949-59.
  25. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends in Immunology. 2012 Jun;33(6):306-14.
  26. Vance RE, Eichberg MJ, Portnoy DA, et al. Listening to each other: Infectious disease and cancer immunology. Science Immunology. 2017 Jan 13;2(7):eaai9939.
  27. Thorme JJC, Grinshpun B, Kumar BV, et al. Long-term maintenance of human naive T cells through in situ homeostatsis in lymphoid tissue sites. Science Immunology. 2016 Dec 16;1(6):eaah6506.
 < Prev  |  1  |  2 


Related Stories

What's Hot in HIV Cure Research?
Gene Therapy to Cure HIV: Where to From Here?
No Proof of New HIV Cure, Despite Headlines -- Here's What We Know
The Only Cases of HIV Cure or Remission
Beyond the Berlin Patient: How Researchers Are Now Trying to Cure More HIV-Positive People (Video)
What Would an HIV Cure Mean for You?



This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.